Neuroendocrine Carcinoma — Trials

Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,533 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 515
Recruiting: 261
Ph III recruiting: 29
Growth YoY: +4.2%
Industry share: 38%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (213)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04677361	Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab	withdrawn	Early Phase 1	0	Fox Chase Cancer CenterOTHER	0	Oct 8, 2021	clinicaltrials

Data updated 22 days agoSource updated Oct 8, 2021source: clinicaltrials